Keywords: Dainippon Sumitomo, Boston Biomedical, License option, Colorectal cancer, Solid turmors
Dainippon Sumitomo licenses cancer drug from Boston Biomedical for up to $100 million
Article | 08 April 2011
In a fourth product rights acquisition in a matter of two weeks, Dainippon Sumitomo Pharma (4506: JP) has signed a product ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
